Antenatal Steroids Don't Cut Morbidity in Preterm Twins

Share this content:
Antenatal Steroids Don't Cut Morbidity in Preterm Twins
Antenatal Steroids Don't Cut Morbidity in Preterm Twins

WEDNESDAY, Aug. 17, 2016 (HealthDay News) -- Antenatal administration of corticosteroids is not associated with a reduction in the incidence of respiratory distress syndrome (RDS) in preterm twins, according to research published in the September issue of Obstetrics & Gynecology.

Oscar A. Viteri, M.D., from the University of Texas Health Science Center at Houston, and colleagues conducted a secondary analysis of a multicenter randomized trial for the prevention of preterm birth in multiple gestations. The authors compared neonatal outcomes for 432 women who received and did not receive antenatal corticosteroids and their 850 neonates.

The researchers found that 35 percent of neonates were born to women receiving antenatal corticosteroids. Antenatal corticosteroids were not associated with reduced incidence of RDS (27 versus 17 percent; adjusted relative risk [aRR], 1.28; 95 percent confidence interval [CI], 0.97 to 1.71) or with composite neonatal morbidity (29 versus 20 percent; aRR, 1.21; 95 percent CI, 0.93 to 1.56). Increased rates of neonatal intensive care unit admissions (78 versus 59 percent; aRR, 1.22; 95 percent CI, 1.09 to 1.36) and mechanical ventilation (23 versus 12 percent; aRR, 1.52; 95 percent CI, 1.12 to 2.09) were seen in association with antenatal corticosteroids. Similar results were seen for RDS and neonatal morbidity in analysis focusing on 311 newborns delivered before 34 weeks of gestation.

"In this cohort of preterm twins, antenatal corticosteroid administration was not associated with a reduced incidence of RDS and composite neonatal morbidity," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »